{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T19:09:42Z","timestamp":1789844982843,"version":"4.0.1"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    Kyasanur Forest Disease Virus (KFDV) is a zoonotic tick-borne flavivirus that causes Kyasanur Forest Disease (KFD), a disease primarily found in India. KFD historically been confined to Karnataka state of southern India, however, in recent years, it has spread beyond its original endemic region, raising significant public health concerns. There are currently no KFD specific treatments or vaccines available. Rapid development of effective vaccine against KFD is urgently needed. We developed and evaluated a whole virion inactivated KFD virus vaccine candidate, adjuvanted with aluminum hydroxide [Al(OH)3] for its safety and efficacy in laboratory animal models. We used a well-characterized KFD virus strain and an established Vero cell platform to produce large-scale GMP-grade highly purified inactivated antigen. Two dose vaccination with the vaccine candidate (18 \u00b5g\/dose) in Balb\/c mice model elicited stronger IgG response and elevated neutralizing antibody as well as T cell cytokines responses and provided complete protection against KFDV challenge (100 LD\n                    <jats:sub>50<\/jats:sub>\n                    ). The protected mice in vaccinated group showed reduced weight loss, controlled clinical symptoms and significantly low viral load in brain tissue. Passive transfer of KFD vaccine immune serum provided effective protection to naive mice against a lethal KFDV challenge (10 LD\n                    <jats:sub>50<\/jats:sub>\n                    ). Single-dose and repeated-dose toxicity evaluation demonstrated that the vaccine is well tolerated, safe, and non-toxic. Our preclinical results support further advancement to human clinical trials and have obtained CDSCO approval for Phase I testing.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2026.1786057","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T05:25:47Z","timestamp":1775107547000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Development of whole virion inactivated Kyasanur Forest Disease vaccine candidate and its preclinical safety and efficacy evaluation"],"prefix":"10.3389","volume":"17","author":[{"given":"Raju","family":"Sunagar","sequence":"first","affiliation":[{"name":"Indian Immunologicals Ltd","place":["Hyderabad, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narayana","family":"Penta","sequence":"additional","affiliation":[{"name":"Indian Immunologicals Ltd","place":["Hyderabad, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sreelekshmy","family":"Mohandas","sequence":"additional","affiliation":[{"name":"Maximum Containment Facility, Indian Council of Medical Research-National Institute of Virology","place":["Pune, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rekha","family":"Cheruvara","sequence":"additional","affiliation":[{"name":"Indian Immunologicals Ltd","place":["Hyderabad, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rama Lakshmi","family":"Bonda","sequence":"additional","affiliation":[{"name":"Indian Immunologicals Ltd","place":["Hyderabad, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Praveen","family":"Algangula","sequence":"additional","affiliation":[{"name":"Indian Immunologicals Ltd","place":["Hyderabad, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virendra Kumar","family":"Meena","sequence":"additional","affiliation":[{"name":"Electron Microscopy and Histopathology laboratory, ICMR-National Institute of Virology","place":["Pune, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sathish","family":"Kumar","sequence":"additional","affiliation":[{"name":"Indian Immunologicals Ltd","place":["Hyderabad, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sridevi","family":"Nimmagadda","sequence":"additional","affiliation":[{"name":"Indian Immunologicals Ltd","place":["Hyderabad, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jitendra","family":"Narayan","sequence":"additional","affiliation":[{"name":"Division of Communicable Diseases, Indian Council of Medical Research","place":["New Delhi, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nivedita","family":"Gupta","sequence":"additional","affiliation":[{"name":"Division of Communicable Diseases, Indian Council of Medical Research","place":["New Delhi, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pragya Dhruv","family":"Yadav","sequence":"additional","affiliation":[{"name":"Maximum Containment Facility, Indian Council of Medical Research-National Institute of Virology","place":["Pune, India"]},{"name":"Indian Council of Medical Research-National Institute of One Health","place":["Nagpur, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anand Kumar","family":"Kanakasapapathy","sequence":"additional","affiliation":[{"name":"Indian Immunologicals Ltd","place":["Hyderabad, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,2]]},"reference":[{"key":"B1","article-title":"Kyasanur forest disease. III. A preliminary report on the nature of the infection and clinical manifestations in human beings","volume":"11","author":"Work","year":"1957","journal-title":"Indian J Med Sci"},{"key":"B2","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1029\/2018gh000164","article-title":"Historical expansion of Kyasanur Forest Disease in India from 1957 to 2017: A retrospective analysis","volume":"3","author":"Chakraborty","year":"2019","journal-title":"Geohealth"},{"key":"B3","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s40249-015-0066-9","article-title":"On the transmission pattern of Kyasanur Forest disease (KFD) in India","volume":"4","author":"Murhekar","year":"2015","journal-title":"Infect Dis Povert"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/zph.12349","article-title":"Kyasanur forest disease virus breaking the endemic barrier: An investigation into ecological effects on disease emergence and future outlook","volume":"64","author":"Ajesh","year":"2017","journal-title":"Zoo Public Health"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.65228","article-title":"Kyasanur Forest Disease: A comprehensive review","volume":"16","author":"N","year":"2024","journal-title":"Cureus"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/s1473-3099(25)00589-4","article-title":"Kyasanur Forest disease: An emerging arboviral threat","volume":"25","author":"Pandey","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.20944\/preprints202505.1961.v1","article-title":"Kyasanur Forest Disease Virus: Epidemiological insights, pathogenesis, therapeutic strategies, and advances in vaccines and diagnostics","volume":"17","author":"Bohra","year":"2025","journal-title":"Viruses"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.4103\/ijmr.ijmr_688_17","article-title":"Clinical & epidemiological significance of Kyasanur forest disease","volume":"148","author":"Munivenkatappa","year":"2018","journal-title":"Indian J Med Res"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinpr.2024.100352","article-title":"Kyasanur Forest Disease: Clinical manifestations and molecular dynamics in a zoonotic landscape","volume":"21","author":"Verma","year":"2024","journal-title":"Clin Infect Pract"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.495","article-title":"Kyasanur forest disease: An epidemiological view in India","volume":"16","author":"Pattnaik","year":"2006","journal-title":"Rev Med Virol"},{"key":"B11","article-title":"Field evaluation of formalin inactivated Kyasanur forest disease virus tissue culture vaccine in three districts of Karnataka state","volume":"99","author":"Dandawate","year":"1994","journal-title":"Indian J Med Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3201\/eid1902.120544","article-title":"Kyasanur forest disease, India, 2011-2012","volume":"19","author":"Kasabi","year":"2013","journal-title":"Emerg Infect Dis"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0002025","article-title":"Coverage and effectiveness of Kyasanur forest disease (KFD) vaccine in Karnataka, South India, 2005-10","volume":"7","author":"Kasabi","year":"2013","journal-title":"PloS NeglTr Dis"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1080\/21505594.2025.2580154","article-title":"Pathogenicity and virulence of Kyasanur Forest disease: A comprehensive review of an expanding zoonotic threat in southwestern India","volume":"16","author":"Kaushal","year":"2025","journal-title":"Virulence"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1038\/s41598-020-58242-w","article-title":"Phylogeography of Kyasanur Forest Disease virus in India (1957-2017) reveals evolution and spread in the Western Ghats region","volume":"10","author":"Yadav","year":"2020","journal-title":"Sci Rep"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.3390\/biomedicines11071871","article-title":"Evaluation of safety and potency of kyasanur forest disease (KFD) vaccine inactivated with different concentrations of formalin and comparative evaluation of in vitro and in vivo methods of virus titration in KFD vaccine","volume":"11","author":"Srikanth","year":"2023","journal-title":"Biomedicines"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01809-14","article-title":"Effect of formaldehyde inactivation on poliovirus","volume":"88","author":"Wilton","year":"2014","journal-title":"J Virol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0004167","article-title":"Formalin inactivation of Japanese Encephalitis Virus vaccine alters the antigenicity and immunogenicity of a neutralization epitope in envelope protein domain III","volume":"9","author":"Fan","year":"2015","journal-title":"PloS NeglTr Dis"},{"key":"B19","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1126\/science.abc1932","article-title":"Development of an inactivated vaccine candidate for SARS-CoV-2","volume":"369","author":"Gao","year":"2020","journal-title":"Science"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1089\/vim.2023.0107","article-title":"Cellular immune responses against gamma-inactivated antigen in the recovered cases of Kyasanur Forest Disease","volume":"37","author":"Kaushal","year":"2024","journal-title":"Viral Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.psj.2025.104878","article-title":"Assessing the effect of beta-propiolactone inactivation on the antigenicity and immunogenicity of cluster 2.1 duck Tembusu virus","volume":"104","author":"Rungprasert","year":"2025","journal-title":"Poult Sci"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.2100","article-title":"The role of anti-flavivirus humoral immune response in protection and pathogenesis","volume":"30","author":"Hurtado-Monzon","year":"2020","journal-title":"Rev Med Virol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1038\/s41541-021-00416-2","article-title":"A live-attenuated viral vector vaccine protects mice against lethal challenge with Kyasanur Forest disease virus","volume":"6","author":"Bhatia","year":"2021","journal-title":"NPJ Vaccines"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adj1428","article-title":"Single-dose VSV-based vaccine protects against Kyasanur Forest disease in nonhuman primates","volume":"9","author":"Bhatia","year":"2023","journal-title":"Sci Adv"},{"key":"B25","doi-asserted-by":"publisher","first-page":"15306","DOI":"10.1038\/s41598-020-72205-1","article-title":"Dynamics of human B and T cell adaptive immune responses to Kyasanur Forest disease virus infection","volume":"10","author":"Devadiga","year":"2020","journal-title":"Sci Rep"},{"key":"B26","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.ijregi.2023.02.003","article-title":"Does the rise in cases of Kyasanur forest disease call for the implementation of One Health in India","volume":"7","author":"Pattnaik","year":"2023","journal-title":"IJID Reg"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01096-16","article-title":"Protective capacity of the human anamnestic antibody response during acute dengue virus infection","volume":"90","author":"Xu","year":"2016","journal-title":"J Virol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s40506-020-00242-5","article-title":"Japanese encephalitis vaccines","volume":"12","author":"Satchidanandam","year":"2020","journal-title":"Curr Treat Opt Infect Dis"},{"key":"B29","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ebiom.2017.12.010","article-title":"Passive transfer of immune sera induced by a Zika virus-like particle vaccine protects AG129 mice against lethal Zika virus challenge","volume":"27","author":"Espinosa","year":"2018","journal-title":"EBioMedicine"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1128\/mbio.01123-16","article-title":"Dengue virus envelope dimer epitope monoclonal antibodies isolated from dengue patients are protective against Zika virus","volume":"7","author":"Swanstrom","year":"2016","journal-title":"mBio"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.06.062","article-title":"Correlation of protection against Japanese encephalitis virus and JE vaccine (IXIARO((R))) induced neutralizing antibody titers","volume":"29","author":"Van Gessel","year":"2011","journal-title":"Vaccine"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.77.4.2578-2586.2003","article-title":"B cells and antibody play critical roles in the immediate defense of disseminated infection by West Nile encephalitis virus","volume":"77","author":"Diamond","year":"2003","journal-title":"J Virol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00334","article-title":"Cross-reactive immunity among flaviviruses","volume":"11","author":"Rathore","year":"2020","journal-title":"Front Immunol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.microb.2024.100105","article-title":"Flavivirus cross-reactivity: Insights into e-protein conservancy, pre-existing immunity, and co-infection","volume":"4","author":"Uhuami","year":"2024","journal-title":"Microbe"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1786057\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T05:25:48Z","timestamp":1775107548000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1786057\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,2]]},"references-count":34,"alternative-id":["10.3389\/fimmu.2026.1786057"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1786057","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,2]]},"article-number":"1786057"}}